Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia The NODE-302 Trial (Extension of NODE-301)

NCT03635996 is registered in ClinicalTrials.gov with Milestone Pharmaceuticals Inc. as lead sponsor.

NCT NCT03635996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03635996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia The NODE-302 Trial (Extension of NODE-301)
Lead sponsor
Milestone Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Terminated
Start date
December 10, 2018
Completion date
November 13, 2020
Enrollment
169 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal supraventricular tachycardia